FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128475101> ?p ?o ?g. }

• W2128475101 endingPage "479" @default.
• W2128475101 startingPage "470" @default.
• W2128475101 abstract "Lubiprostone, a bicyclic fatty acid derived from prostaglandin E1, has been used to treat chronic constipation and irritable bowel syndrome, and its mechanism of action has been attributed to the stimulation of intestinal fluid secretion via the activation of the chloride channel protein 2/cystic fibrosis transmembrane regulator (ClC-2/CFTR) chloride channels. We examined the effects of lubiprostone on indomethacin-induced enteropathy and investigated the functional mechanisms involved, including its relationship with the EP4 receptor subtype. Male Sprague-Dawley rats were administered indomethacin (10 mg/kg p.o.) and killed 24 hours later to examine the hemorrhagic lesions that developed in the small intestine. Lubiprostone (0.01-1 mg/kg) was administered orally twice 30 minutes before and 9 h after the indomethacin treatment. Indomethacin markedly damaged the small intestine, accompanied by intestinal hypermotility, a decrease in mucus and fluid secretion, and an increase in enterobacterial invasion as well as the up-regulation of inducible nitric-oxide synthase (iNOS) and tumor necrosis factor α (TNFα) mRNAs. Lubiprostone significantly reduced the severity of these lesions, with the concomitant suppression of the functional changes. The effects of lubiprostone on the intestinal lesions and functional alterations were significantly abrogated by the coadministration of AE3-208 [4-(4-cyano-2-(2-(4-fluoronaphthalen-1-yl)propionylamino)phenyl)butyric acid], a selective EP4 antagonist, but not by CFTR(inh)-172, a CFTR inhibitor. These results suggest that lubiprostone may prevent indomethacin-induced enteropathy via an EP4 receptor-dependent mechanism. This effect may be functionally associated with the inhibition of intestinal hypermotility and increase in mucus/fluid secretion, resulting in the suppression of bacterial invasion and iNOS/TNFα expression, which are major pathogenic events in enteropathy. The direct activation of CFTR/ClC-2 chloride channels is not likely to have contributed to the protective effects of lubiprostone." @default.
• W2128475101 created "2016-06-24" @default.
• W2128475101 creator A5049280193 @default.
• W2128475101 creator A5057615649 @default.
• W2128475101 creator A5058370588 @default.
• W2128475101 creator A5068561789 @default.
• W2128475101 creator A5090713682 @default.
• W2128475101 date "2014-04-08" @default.
• W2128475101 modified "2023-10-14" @default.
• W2128475101 title "Lubiprostone Prevents Nonsteroidal Anti-Inflammatory Drug–Induced Small Intestinal Damage by Suppressing the Expression of Inflammatory Mediators via EP4 Receptors" @default.
• W2128475101 cites W1498652172 @default.
• W2128475101 cites W1544452181 @default.
• W2128475101 cites W1564267641 @default.
• W2128475101 cites W1606919860 @default.
• W2128475101 cites W1919469207 @default.
• W2128475101 cites W1977825904 @default.
• W2128475101 cites W1985079375 @default.
• W2128475101 cites W1987231061 @default.
• W2128475101 cites W1995636631 @default.
• W2128475101 cites W1999059100 @default.
• W2128475101 cites W2000978731 @default.
• W2128475101 cites W2002924275 @default.
• W2128475101 cites W2011666294 @default.
• W2128475101 cites W2012346814 @default.
• W2128475101 cites W2014753452 @default.
• W2128475101 cites W2017993067 @default.
• W2128475101 cites W2018903949 @default.
• W2128475101 cites W2021521740 @default.
• W2128475101 cites W2023716422 @default.
• W2128475101 cites W2030064920 @default.
• W2128475101 cites W2036112383 @default.
• W2128475101 cites W2038438200 @default.
• W2128475101 cites W2039342085 @default.
• W2128475101 cites W2045763309 @default.
• W2128475101 cites W2054305086 @default.
• W2128475101 cites W2059605635 @default.
• W2128475101 cites W2082793372 @default.
• W2128475101 cites W2085947237 @default.
• W2128475101 cites W2086529488 @default.
• W2128475101 cites W2089344272 @default.
• W2128475101 cites W2089598730 @default.
• W2128475101 cites W2092237979 @default.
• W2128475101 cites W2097086662 @default.
• W2128475101 cites W2101851685 @default.
• W2128475101 cites W2106761389 @default.
• W2128475101 cites W2111015948 @default.
• W2128475101 cites W2114567997 @default.
• W2128475101 cites W2134782997 @default.
• W2128475101 cites W2155862827 @default.
• W2128475101 cites W2156953890 @default.
• W2128475101 cites W2166509514 @default.
• W2128475101 cites W270039881 @default.
• W2128475101 doi "https://doi.org/10.1124/jpet.114.213991" @default.
• W2128475101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24713141" @default.
• W2128475101 hasPublicationYear "2014" @default.
• W2128475101 type Work @default.
• W2128475101 sameAs 2128475101 @default.
• W2128475101 citedByCount "35" @default.
• W2128475101 countsByYear W21284751012014 @default.
• W2128475101 countsByYear W21284751012015 @default.
• W2128475101 countsByYear W21284751012016 @default.
• W2128475101 countsByYear W21284751012017 @default.
• W2128475101 countsByYear W21284751012018 @default.
• W2128475101 countsByYear W21284751012019 @default.
• W2128475101 countsByYear W21284751012020 @default.
• W2128475101 countsByYear W21284751012021 @default.
• W2128475101 countsByYear W21284751012022 @default.
• W2128475101 countsByYear W21284751012023 @default.
• W2128475101 crossrefType "journal-article" @default.
• W2128475101 hasAuthorship W2128475101A5049280193 @default.
• W2128475101 hasAuthorship W2128475101A5057615649 @default.
• W2128475101 hasAuthorship W2128475101A5058370588 @default.
• W2128475101 hasAuthorship W2128475101A5068561789 @default.
• W2128475101 hasAuthorship W2128475101A5090713682 @default.
• W2128475101 hasConcept C126322002 @default.
• W2128475101 hasConcept C134018914 @default.
• W2128475101 hasConcept C170493617 @default.
• W2128475101 hasConcept C185592680 @default.
• W2128475101 hasConcept C202751555 @default.
• W2128475101 hasConcept C2776120743 @default.
• W2128475101 hasConcept C2776938444 @default.
• W2128475101 hasConcept C2777956040 @default.
• W2128475101 hasConcept C2778426112 @default.
• W2128475101 hasConcept C2778428886 @default.
• W2128475101 hasConcept C2779134260 @default.
• W2128475101 hasConcept C2780664492 @default.
• W2128475101 hasConcept C2781093762 @default.
• W2128475101 hasConcept C2781112942 @default.
• W2128475101 hasConcept C3017955636 @default.
• W2128475101 hasConcept C55493867 @default.
• W2128475101 hasConcept C71924100 @default.
• W2128475101 hasConcept C98274493 @default.
• W2128475101 hasConceptScore W2128475101C126322002 @default.
• W2128475101 hasConceptScore W2128475101C134018914 @default.
• W2128475101 hasConceptScore W2128475101C170493617 @default.
• W2128475101 hasConceptScore W2128475101C185592680 @default.
• W2128475101 hasConceptScore W2128475101C202751555 @default.
• W2128475101 hasConceptScore W2128475101C2776120743 @default.

• next